Analysts think GPCR stock price could increase by 119%
Oct 15, 2025, 11:25 AM
15.92%
What does GPCR do
Structure Therapeutics, a clinical stage biopharmaceutical company based in South San Francisco, focuses on developing oral therapeutics targeting GPCRs for chronic diseases. It went public on February 3, 2023, and employs 111 people.
15 analysts think GPCR stock price will increase by 119.39%. The current median analyst target is $66.30 compared to a current stock price of $30.22. The lowest analysts target is $50.50 and the highest analyst target is $126.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.